Loading...

TENX TENAX THERAPEUTICS INC US FDA Inspections 8-K Filing

TNX

TNX

TENAX THERAPEUTICS INC

(TENX)

2023 8-K

Show Summary

Show Summary

Financial Statements

Financial Results

Private Placement

Management Change

Q3 Financial Results

Stock Plan Amendment

Q2 Financial Results

Private Placement

Annual Meeting and Director...

Financial Results Announcement

Financial Results Announcement

Compliance regained with Na...

Amendment to License Agreement

Public Offering

Enrollment in Phase 3 Study

Patent Allowed for Use of D...

Compliance Regained with Na...

Delisting Notice

Reverse Stock Split

Special Meeting of Stockhol...

FDA Clearance for IND Appli...

Bylaws Amendments

Annual Meeting Results

Patent Approval

Lease Termination

Public Offering

Patent Approval

Compliance with Nasdaq List...

Reverse Stock Split

External Links:

Tenax Therapeutics, Inc. announces FDA clearance for IND Application for TNX-103 for treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) and initiation of Phase 3 sites in Q4 2023.

AI Assistant

TENAX THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.